Vimarsana
Biggest News Aggregation in the World

Page 9 - Acceleron Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acceleron Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acceleron Pharma Today - Breaking & Trending Today

Merck's blood vessel disorder therapy receives US FDA's priority review - Vimarsana News

Merck's blood vessel disorder therapy receives US FDA's priority review

The drugmaker had gained rights to the therapy, sotatercept, through its $11.5 billion acquisition of Acceleron Pharma in 2021. The U.S. Food and Drug Administration has set March 26, 2024 as a target action date for the review, Merck said. If approved, the therapy will help the U.S. drugmaker diversify its revenue stream as its blockbuster cancer immunotherapy, Keytruda, moves towards loss of market exclusivity in 2028.

Source: yahoo.com
Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH) - Vimarsana News

Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)

Application based on clinically meaningful results from the Phase 3 STELLAR trial If approved, sotatercept would be the first in its class, bringing a novel approach to address a rare and...

FDA gives Merck priority review for blood vessel disorder therapy sotatercept - Vimarsana News

FDA gives Merck priority review for blood vessel disorder therapy sotatercept

Merck acquired sotatercept for $11.5 billion from Acceleron Pharma in 2021 as part of a play to expand its cardiovascular pipeline.

Laboratorios Farmaceuticos Rovi (OTCMKTS:LABFF) versus Fulcrum Therapeutics (NASDAQ:FULC) Critical Review - Vimarsana News

Laboratorios Farmaceuticos Rovi (OTCMKTS:LABFF) versus Fulcrum Therapeutics (NASDAQ:FULC) Critical Review

Laboratorios Farmaceuticos Rovi (OTCMKTS:LABFF – Get Free Report) and Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings. Institutional and Insider Ownership 89.8% of Fulcrum […]

3 Reasons to Buy Merck Stock | The Motley Fool - Vimarsana News

3 Reasons to Buy Merck Stock | The Motley Fool

This list is by no means exhaustive.

Source: fool.com